Prothena (NASDAQ:PRTA – Get Free Report) and Relay Therapeutics (NASDAQ:RLAY – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.
Volatility and Risk
Prothena has a beta of -0.2, suggesting that its stock price is 120% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500.
Insider & Institutional Ownership
97.1% of Prothena shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Prothena and Relay Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prothena | $9.68 million | 43.29 | -$244.09 million | ($0.48) | -17.00 |
| Relay Therapeutics | $15.35 million | 260.40 | -$276.48 million | ($1.51) | -11.98 |
Prothena has higher earnings, but lower revenue than Relay Therapeutics. Prothena is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and target prices for Prothena and Relay Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prothena | 1 | 1 | 3 | 2 | 2.86 |
| Relay Therapeutics | 1 | 1 | 11 | 1 | 2.86 |
Prothena presently has a consensus target price of $20.00, suggesting a potential upside of 145.10%. Relay Therapeutics has a consensus target price of $27.00, suggesting a potential upside of 49.25%. Given Prothena’s higher probable upside, equities research analysts plainly believe Prothena is more favorable than Relay Therapeutics.
Profitability
This table compares Prothena and Relay Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prothena | -45.44% | -9.98% | -9.08% |
| Relay Therapeutics | N/A | -40.25% | -36.82% |
Summary
Prothena beats Relay Therapeutics on 8 of the 14 factors compared between the two stocks.
About Prothena
Prothena Corporation plc is a clinical-stage biotechnology company developing treatments for diseases associated with protein misfolding and dysfunction. Its research focuses on using antibodies and other biologic approaches to target proteins implicated in neurological and systemic disorders. The company’s pipeline has included programs for Parkinson’s disease, Alzheimer’s disease and AL amyloidosis. Its investigational therapies include prasinezumab, developed in collaboration with Roche, and programs targeting amyloid beta and transthyretin-related disease.
About Relay Therapeutics
Relay Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines for patients with serious diseases, with an emphasis on cancer. The company uses its computational drug discovery platform to study how proteins move and interact, aiming to identify drug targets and design therapies against them. Relay’s research combines experimental biology, structural biology and computational methods. Its drug development programs have included candidates targeting cancer-related pathways, such as FGFR2 and PI3Kα.
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.
